- Collink.3D™ 90 offers additional functionality to
address wide range of 3D bioprinting applications, including soft
and hard tissues
- Collink.3D™ 90 demonstrates faster human cell
migration into gel matrices compared with a commercial hydrogel
widely used for 2D and 3D cell culture
- Second bioink launch advances Company's strategic goal to
build portfolio of rhCollagen-based bioinks for biopharma and
academic customers
REHOVOT, Israel, Nov. 7, 2022
/PRNewswire/ -- CollPlant (Nasdaq:
CLGN), a regenerative and aesthetics medicine company
developing innovative human collagen-based technologies and
products for tissue regeneration and organ manufacturing, today
announced the Company is launching Collink.3D™ 90, a
recombinant human collagen (rhCollagen)-based bioink for use in a
variety of 3D bioprinting applications. Collink.3D™ 90 is
complementary to the Company's first commercial bioink,
Collink.3D™ 50, which was launched late last year, offering
increased mechanical properties to address additional printing
requirements of soft and hard tissues.
Bioinks are applied to a diverse range of soft and hard tissue
engineering applications, with each tissue or organ having specific
mechanical requirements for fulfilling physiological needs. Thus,
the most suitable bioink is required for a given application to
mimic the physical properties of the target tissue or organ, while
ensuring high cell survival.
"We are very excited to continue to broaden our rhCollagen-based
bioink offerings, providing our biopharma and academic customers
the ability to print a variety of applications," said CollPlant
CEO, Yehiel Tal. "We believe our
bioinks deliver a favorable alternative to existing commercial
bioinks owing to their high bio-functionality, rheological
properties (e.g., controlled viscosity) and high purity. In
addition to our product pipeline, bioinks are an important and
strategic platform that supports CollPlant's efforts to pursue
licensing and collaboration agreements with business partners, and
we will continue to introduce new bioinks and innovate in this
area", he added.
Collink.3D™ 90 demonstrates faster human cell migration
into gel matrices compared with a commercial hydrogel widely used
for 2D and 3D cell culture. Cell migration plays a pivotal role in
physiological processes such as tissue repair and regeneration, and
these initial results indicate the potential for
Collink.3D™ 90 to perform as a superior, animal free, human
cell culture substrate.
Collink.3D™ enables the high-resolution, scalable and
reproduceable 3D bioprinting of scaffolds that accurately mimic the
physical properties of human tissues and organs, with improved
biofunctionality, safety and reproducibility. Applications for
Collink.3D™ include its use in 3D cell culturing, tissue
modeling for drug discovery and development, as well as engineering
tissues and implantation of organs in regenerative medicine,
representing a potential multi-billion-dollar market opportunity.
Biofabricated constructs composed of Collink.3D™ offer
superior biological performance, consistency and safety.
Collink.3D™ is compatible with major 3D bioprinting
technologies and cell types including stem cells, induced
pluripotent stem cells, endothelial, and epithelial cells.
More information can be found
on https://collplant.com/products/collink3d/
Contact us for more details collink3d@collplant.com
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. The Company's products are based on its rhCollagen
(recombinant human collagen) produced with CollPlant's proprietary
plant based genetic engineering technology. These products address
indications for the diverse fields of tissue repair, aesthetics,
and organ manufacturing, and are ushering in a new era in
regenerative and aesthetic medicine.
In 2021 CollPlant entered into a development and global
commercialization agreement for dermal and soft tissue fillers with
Allergan, an AbbVie company, the global leader in the dermal filler
market. For more information about CollPlant, visit
http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the impact of the COVID-19
pandemic; the Company's expectations regarding the timing and cost
of commencing clinical trials with respect to tissues and organs
which are based on its rhCollagen based BioInk and products for
medical aesthetics; the Company's ability to obtain favorable
pre-clinical and clinical trial results; regulatory action with
respect to rhCollagen based BioInk and medical aesthetics products
including but not limited to acceptance of an application for
marketing authorization review and approval of such application,
and, if approved, the scope of the approved indication and
labeling; commercial success and market acceptance of the Company's
rhCollagen based products in 3D Bioprinting and medical aesthetics;
the Company's ability to establish sales and marketing capabilities
or enter into agreements with third parties and its reliance on
third party distributors and resellers; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the Company's reliance on third parties to conduct
some or all aspects of its product manufacturing; the scope of
protection the Company is able to establish and maintain for
intellectual property rights and the Company's ability to operate
its business without infringing the intellectual property rights of
others; the overall global economic environment; the impact of
competition and new technologies; general market, political, and
economic conditions in the countries in which the Company operates;
projected capital expenditures and liquidity; changes in the
Company's strategy; and litigation and regulatory proceedings. More
detailed information about the risks and uncertainties affecting
CollPlant is contained under the heading "Risk Factors" included in
CollPlant's most recent annual report on Form 20-F filed with the
SEC, and in other filings that CollPlant has made and may make with
the SEC in the future. The forward-looking statements contained in
this press release are made as of the date of this press release
and reflect CollPlant's current views with respect to future
events, and CollPlant does not undertake and specifically disclaims
any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Photo -
https://mma.prnewswire.com/media/1939402/Collink_90_launch.jpg
Contact at CollPlant:
Eran
Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@CollPlant.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/collplant-expands-rhcollagen-based-bioink-platform-with-launch-of-collink3d-90-301670042.html
SOURCE CollPlant